Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Investing

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

by April 12, 2024
April 12, 2024
CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Highlights

CLEO has appointed U.S.-based Lindus Health to manage U.S. clinical trials for its revolutionary ovarian cancer blood testLindus Health is a leader in clinical trial management for the med-tech sector, with a strong record of timely and successful trial executionCLEO’s U.S. study will prospectively recruit up to 500 patients commencing next month and will verify the performance of CLEO’s pre-surgical ovarian cancer test for FDA regulatory approval.

U.S. Ovarian Cancer Clinical Trials

As a part of CLEO’s U.S. market access program, the Company will partner with U.S.-based CRO, Lindus Health, appointing it to manage the successful execution of its ovarian cancer U.S. clinical trials. Lindus Health was chosen following a robust process to identify a partner with the proven experience, technology and high standards capable of delivering on CLEO’s objectives.

Lindus Health specialises in collaborating with med-tech companies to conduct clinical trials worldwide, leveraging their innovative patient recruitment and trial management technology platform to deliver efficient and timely outcomes.

Comprehensive U.S. patient data is essential for a successful regulatory application through the Food and Drug Administration (FDA). CLEO will leverage Lindus Health’s expertise to execute a cost-effective and rapid clinical study that will support its subsequent FDA 510(k) application.

The study will benchmark CLEO’s pre-surgical ovarian cancer triage test and provide the core data requirements for the FDA 510(k) application. Up to 500 U.S.-based patients will be recruited, with the trial scheduled over 10 months following ethic approvals and site engagement.

An Australian arm of the trial will also run concurrently and be managed directly by CLEO. This dual- arm strategy mitigates risk to the timelines due to patient recruitment, and will provide additional patient samples for kit verification following manufacture.

The study data will be published in the mainstream medical literature as a part of CLEO’s rigorous publication strategy.

Commenting on the partnership with Lindus Health, CLEO Chief Executive, Richard Allman, said:

“With the appointment of Lindus Health, our U.S. market access program is well underway to achieve our goal of obtaining regulatory approval for CLEO’s initial pre-surgical market in the U.S. for our ovarian cancer blood test.

CLEO is appointing high calibre partners that we believe will help us deliver our important ovarian cancer detection technology to improve the health outcomes for women.”

Click here for the full ASX Release

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Multiple Work Programs Underway and Planned at Radium Point, Coppermine & Reedy South Projects
next post
Carbon Done Right Announces Brokered Private Placement

Related Posts

1911 Gold Temporarily Suspends Operations at True North...

May 31, 2025

GTI Energy Ltd (ASX: GTR) – Trading Halt

June 17, 2024

Argo Launches Digital Gold Investment Platform in the...

February 27, 2025

Investing in Uranium ETFs: 9 Options for Uranium...

May 10, 2025

Grid Battery Exploration Team begins work on its...

March 29, 2024

Placement of Shortfall and Cleansing Notice

February 26, 2025

Group Eleven Announces Appointment of Jasmine Lau as...

May 30, 2025

Avrupa Minerals Ltd. 2023 Progress and 2024 Plans

February 22, 2024

Zinc Price 2023 Year-End Review

January 10, 2024

Rio Tinto Delivers Resilient Q1 Performance, Commits to...

April 19, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • How I Triple My Returns With 3x Leveraged ETFs!

    • How to Find Compelling Charts in Every Sector

    • EVs Now Emit 73 percent Less Than Gasoline Cars Over Their Lifetime, Says ICCT Study

    • Cygnus Metals Limited: Issue of Performance Rights

    • FPX Nickel Announces Share-Based Compensation Grant

    • Blue Lagoon Resources Officially Opens Dome Mountain Gold Mine in British Columbia

    Categories

    • Business (1,287)
    • Investing (2,662)
    • Politics (3,699)
    • Stocks (1,711)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved